Bluefin Capital Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Bluefin Capital Management’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-30,273	Closed	-$1.88M	–	644
2022 Q1	$1.88M	Sell	30,273 -7,792	-20%	-$477K	0.17%	86
2021 Q4	$2.1M	Buy	38,065 +24,325	+177%	+$1.27M	0.15%	119
2021 Q3	$723K	Buy	+13,740	New	+$816K	0.07%	201

Other funds holding LKFT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bluefin Capital Management's LKFT Position: Q2 2022 in Review

Bluefin Capital Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2022, closing a stake of 30,273 shares — an estimated $1.88M sold.

Bluefin Capital Management first reported a position in LKFT in Q3 2021 and held it in 3 quarters. The position peaked at $2.1M in Q4 2021. 82 funds tracked by Wall St. Rank hold LKFT as of Q2 2022.

Bluefin Capital Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2022 after selling out during the quarter.
Bluefin Capital Management sold 30,273 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2022, an estimated $1.88M.
Bluefin Capital Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2021 and held it in 3 quarters.
Bluefin Capital Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $2.1M in Q4 2021.
82 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2022.

Based on Bluefin Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.